Welcome to our dedicated page for Smith & Nephew Plc SEC filings (Ticker: SNNUF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Smith & Nephew Plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Smith & Nephew Plc's regulatory disclosures and financial reporting.
Smith & Nephew plc reports that its new debt securities have been admitted to trading on the Main Market of the London Stock Exchange. The company has listed EUR 500,000,000 of 4.250 per cent. notes due 3 June 2038, issued under its U.S.$5,000,000,000 Euro Medium Term Note Programme.
The notes are supported by a base prospectus dated 17 March 2026 and a supplemental prospectus dated 15 May 2026, together forming the Prospectus. Investors are directed to the Prospectus and Final Terms, which are available online, and are reminded that the information is intended only for specified addressees as set out in those documents.
Smith & Nephew plc reports its latest share capital and voting rights position as at 31 May 2026. The company has total issued share capital of 877,733,750 ordinary shares of US20¢ each, of which 27,524,042 are held in treasury.
Because treasury shares do not carry voting rights, the company’s issued share capital with voting rights consists of 850,209,708 ordinary shares, each with one vote. Shareholders are asked to use this voting share figure as the denominator when assessing whether they must notify holdings or changes under the FCA’s Disclosure Guidance and Transparency Rules.
Smith & Nephew plc reports that an additional 8,905 Ordinary Shares of USD 0.20 each have been issued and admitted to trading on the Main Market of the London Stock Exchange. These shares arise from the company’s employee share schemes between 23 March 2026 and 21 May 2026 under an existing block admission dated 12 August 2022. Following this admission, there are 877,733,750 Ordinary Shares in issue, of which 26,452,529 are held in treasury.
Smith & Nephew plc reported the vesting of conditional share awards under its Global Share Plan 2020 for senior executive Rohit Kashyap. On 19 May 2026, Kashyap received 11,949 ordinary shares of US$0.20 each, listed on the London Stock Exchange.
Of these, 4,719 shares were sold to meet tax obligations at a price of £11.426512 per share, while 7,230 shares were retained. The transaction is disclosed as required for persons discharging managerial responsibilities under the UK Market Abuse Regulation.
Smith & Nephew plc reports an updated major shareholding notification from Cevian Capital II G.P. Limited under the UK TR-1 regime. Cevian now holds 11.183442% of Smith & Nephew’s voting rights, representing 95,512,095 voting rights attached to shares.
Within this total, Cevian Capital II Master Fund L.P. accounts for 10.005808% and Cevian Capital II Co-Investment - Series P L.P. accounts for 1.177635%. The aggregate stake has risen from 11.013663%, and the company notes that no new notification threshold has been crossed as a result of this increase.
Smith & Nephew plc reports that investment entities linked to Cevian Capital have crossed a major shareholding threshold. Cevian-controlled funds now hold 94,062,095 voting rights in Smith & Nephew, representing 11.013663% of voting rights attached to shares.
The previous notified position was 10.094356% of voting rights, so this filing records a higher level of ownership. The stake is held through Cevian Capital II Master Fund L.P. with 9.836028% and Cevian Capital II Co-Investment - Series P L.P. with 1.177635%, both ultimately controlled by Cevian Capital II G.P. Limited.
Smith & Nephew plc confirms the sterling amount of its previously announced final dividend for the year ended 31 December 2025. The dividend of 24.1 US cents per ordinary share will be paid on 27 May 2026. Eligible UK-address shareholders or those electing sterling will receive 17.78 pence per share, based on the company’s determined exchange rate, to holders on the register at the close of business on 27 March 2026.
Smith+Nephew has started the first tranche of a share buyback programme, under which Merrill Lynch International will purchase ordinary shares as riskless principal for an aggregate price of up to $250 million. These shares will then be repurchased by Smith+Nephew, held as treasury shares and either cancelled or used to satisfy employee share plans.
The first tranche runs from 8 May 2026 to no later than 7 September 2026, and is intended to return surplus capital to shareholders by reducing issued share capital. The maximum number of ordinary shares the company may purchase under existing authority is 84,988,930 shares, as approved at the 2026 Annual General Meeting.
Smith & Nephew plc reports that shareholders passed all 27 resolutions at its AGM held on 6 May 2026, covering accounts, dividend, director elections, auditor reappointment and share authorities. Most items received very strong support, with many above 95% in favour.
Support for the Directors' Remuneration Policy (Resolution 2) and the Performance Share Plan 2026 (Resolution 21) was lower, at 59.70% and 60.14% respectively. The Board plans further engagement with shareholders and proxy advisers and will provide an update on these consultations within six months, in line with the UK Corporate Governance Code. Ordinary shares in issue were 854,049,145 as of 1 May 2026, with around 84% of relevant shares typically voted on each resolution.
Smith+Nephew reported Q1 2026 revenue of $1,501 million, up 3.1% on an underlying basis and 6.6% reported, helped by a 350bps foreign-exchange tailwind. Growth was broad-based, led by Sports Medicine & ENT and Emerging Markets, while US Knee Implants declined as the company prepares for its new LANDMARK◊ Knee System.
The company announced a new $500 million share buyback to be completed within twelve months, funded from free cash flow and cash balances. Together with ordinary dividends, more than $835 million, or 6.3% of market cap, is expected to be returned to shareholders. Full-year 2026 guidance is unchanged, targeting around 6% underlying revenue growth, around 8% trading profit growth with trading profit around $1.3 billion including Integrity Orthopaedics, around $800 million free cash flow, and greater than 10% adjusted ROIC excluding Integrity Orthopaedics.